SIGA Siga Technologies Inc.

SIGA to Host Business Update Call on August 1 Following Release of Second-Quarter 2024 Financial Results

SIGA to Host Business Update Call on August 1 Following Release of Second-Quarter 2024 Financial Results

NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, August 1, 2024. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.

A live webcast of the call will also be available on the Company's website at in the Investor Relations section of the site, or by . Please log in approximately 5-10 minutes prior to the scheduled start time.

Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers.

A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 11156004. The archived webcast will be available in the Investor Relations section of the .

ABOUT SIGA

SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe and the UK for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit .

Contact:

Investors and Media

Suzanne Harnett





EN
25/07/2024

Underlying

SIGASiga Technologies Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Siga Technologies Inc.

 PRESS RELEASE
Free
SIGA Siga Technologi...

TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxvi...

TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses Regulatory decision marks first approval in Japan of an antiviral for the treatment of orthopoxviruses including smallpox, mpox and cowpoxJapan Biotechno Pharma Co., Ltd. engaged as exclusive distributor to supply TEPOXX to Japan’s national stockpileComprehensive data package demonstrates strong safety profile and robust preclinical efficacy NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, a commercial stage pharmaceutical company, announced today that its antiviral treatment TEPOXX (tecovirim...

January 2, 2025 1 EN
 PRESS RELEASE
Free
SIGA Siga Technologi...

Interim Results from STOMP Study of SIGA’s Tecovirimat in Treatment of...

Interim Results from STOMP Study of SIGA’s Tecovirimat in Treatment of Mpox Announced Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy stopped enrolling patients in all study armsResults affirm tecovirimat’s strong safety profileEfficacy in patients with more severe disease not assessed in study NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- The National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) today announced results from an interim analy...

December 10, 2024 1 EN
Sean Conroy
  • Sean Conroy
SIGA Siga Technologi...

SIGA Technologies - Strong order book moving into Q424

SIGA Technologies reported revenues of $10m in Q324, attributed primarily to deliveries under the $112.5m BARDA option, exercised in July 2024. Backed by a strong order book ($146m at end-Q324), the sales momentum has picked up pace in Q424 with another $51.2m and $8.5m of oral and IV TPOXX (IVT) delivered to the Strategic National Stockpile (SNS) in October 2024. We expect further deliveries in Q424 and early 2025 under the BARDA contract as well as the $9m US Department of Defense (DoD) order ...

SIGA SIGA TECHNOLOGIES INC.
11/18/24 November 18, 2024 1 EN
 PRESS RELEASE
Free
SIGA Siga Technologi...

SIGA Reports Financial Results for Three and Nine Months Ended Septemb...

SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2024 Product Revenues for the Three and Nine months Ended September 30, 2024 were $9 million and $53 million, respectivelyReceived $122 Million of Procurement Orders from the U.S. Government in the Third QuarterCorporate Update Conference Call Today at 4:30 PM ET NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and nine months ended September 30, 2024. “Building on strong momentum,...

November 7, 2024 1 EN
 PRESS RELEASE
Free
SIGA Siga Technologi...

SIGA to Host Business Update Call on November 7 Following Release of T...

SIGA to Host Business Update Call on November 7 Following Release of Third-Quarter 2024 Financial Results NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 7, 2024. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at in the I...

October 31, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch